Chen Ying, Zhou Shuduo, Pei Zhongfei, Zhao Weili, Yang Jian, Hu Yunxuan, Feng Xiangning, Xu Ming
Department of Global Health, School of Public Health, Peking University, Haidian District, 38 Xue Yuan Road, Beijing, China.
Chinese Medical Association, Dongcheng District, 42 Dong Si Xi Road, Beijing, China.
PLoS One. 2025 Jul 9;20(7):e0326422. doi: 10.1371/journal.pone.0326422. eCollection 2025.
The export of traditional Chinese medicinal products is a pivotal force in enhancing the international recognition of Traditional Chinese Medicine (TCM). From 2013 to 2022, the export trend of traditional Chinese medicinal products demonstrated stable and rapid growth. However, the export structure remained suboptimal, with raw material-based products accounting for a significantly larger proportion than high value-added products. This imbalance has hindered the enhancement of traditional Chinese medicinal value and the potential for branding in the global market. Therefore, an in-depth study of the current status and associated factors of the export is essential to optimize the export structure, adjust export policies, and promote the international trade.
We employed joinpoint regression analysis to examine the export value trend of traditional Chinese medicinal products from 2013 to 2022. Subsequently, we utilized stochastic frontier analysis and trade inefficiency analysis to investigate the factors associated with the export value across 182 countries and regions from 2020 to 2022. The export value data was sourced from the China Chamber of Commerce for Import and Export of Medicines and Health Products. The associated factors were sourced from publicly available databases.
Joinpoint regression analysis showed the Annual Average Percent Change (AAPC) of the export value of traditional Chinese medicinal products from 2013 to 2022 was 6.9211 (95% Confidence Interval [CI] 5.9176 to 7.9341). Among them, raw material-based products included Chinese medicinal materials and herbal decoction pieces, as well as plant extracts, with AAPC being 1.7822 (95%CI -3.4203 to 7.2649), and 10.0290 (95%CI 3.5599 to 16.9023), respectively. They comprised over 80% of total exports. High value-added products included Chinese patent medicines and TCM health products, with AAPC being 3.6420 (95%CI -0.7595 to 8.2387) and 17.0895 (95%CI 4.7468 to 30.8865), respectively. They constituted a relatively minor share of total exports. Stochastic frontier analysis showed the coefficient (t-ratio) of factors associated with the export, including China's GDP at 0.0772 (9.3276), the GDP of the export country or region at 0.1240 (3.9521), the capital distance between the export country or region and China at -0.3059 (-8.2793), the population of the export country or region at 0.0329 (3.4657), having a common border with China at -0.3179 (-4.3428), having a common language with China at 1.3316 (13.3217), being a landlocked country or region at -0.3531 (-9.3519). Trade inefficiency analysis showed the coefficient (t-ratio) of associated factors, including having a trade agreement with China at -7.1587 (-38.7960), pharmaceutical products tariffs at 0.2930 (7.7920), cultural distance from China at 0.5995 (7.1274), the overseas registration status of Chinese patent medicines at 2.3608 (13.6945), and the presence of TCM institutions at 6.1643 (16.1009).
The export value of traditional Chinese medicinal products from 2013 to 2022 showed an overall upward trend. However, the export structure remained suboptimal. Stochastic frontier analysis and trade inefficiency analysis revealed the relevance of associated factors to the export value. Based on the above results, we recommend six measures to optimize the export structure and enhance the international recognition of traditional Chinese medicinal products.
中药产品出口是提升中医药国际认可度的关键力量。2013年至2022年,中药产品出口呈稳定快速增长态势。然而,出口结构仍不尽人意,以原材料为基础的产品占比远高于高附加值产品。这种失衡阻碍了中药价值的提升以及在全球市场的品牌塑造潜力。因此,深入研究出口现状及相关因素对于优化出口结构、调整出口政策和促进国际贸易至关重要。
我们采用连接点回归分析来考察2013年至2022年中药产品的出口值趋势。随后,我们利用随机前沿分析和贸易无效率分析来研究2020年至2022年182个国家和地区与出口值相关的因素。出口值数据来自中国医药保健品进出口商会。相关因素来自公开可用数据库。
连接点回归分析显示,2013年至2022年中药产品出口值的年平均变化百分比(AAPC)为6.9211(95%置信区间[CI]5.9176至7.9341)。其中,以原材料为基础的产品包括中药材、中药饮片以及植物提取物,其AAPC分别为1.7822(95%CI -3.4203至7.2649)和10.0290(95%CI 3.5599至16.9023)。它们占出口总额的80%以上。高附加值产品包括中成药和中药保健品,其AAPC分别为3.6420(95%CI -0.7595至8.2387)和17.0895(95%CI 4.7468至30.8865)。它们在出口总额中所占份额相对较小。随机前沿分析显示,与出口相关的因素系数(t值)包括中国国内生产总值为0.0772(9.3276)、出口国家或地区的国内生产总值为0.1240(3.9521)、出口国家或地区与中国的首都距离为-0.3059(-8.2793)、出口国家或地区的人口为0.0329(3.4657)、与中国有共同边界为-0.3179(-4.3428)、与中国有共同语言为1.3316(13.3217)、为内陆国家或地区为-0.3531(-9.3519)。贸易无效率分析显示,相关因素系数(t值)包括与中国有贸易协定为-7.1587(-38.7960)、药品关税为0.2930(7.7920)、与中国的文化距离为0.5995(7.1274)、中成药的海外注册状态为2.3608(13.6945)以及中医机构的存在为6.1643(16.1009)。
2013年至2022年中药产品出口值总体呈上升趋势。然而,出口结构仍不尽人意。随机前沿分析和贸易无效率分析揭示了相关因素与出口值的相关性。基于上述结果,我们建议采取六项措施来优化出口结构并提升中药产品的国际认可度。